



## KAMUYU AYDINLATMA PLATFORMU

# GEN İLAÇ VE SAĞLIK ÜRÜNLERİ SANAYİ VE TİCARET A.Ş. New Business Relation

### Summary

Signature of New Distributorship Agreement



**MERKEZİ KAYIT  
İSTANBUL**  
Türkiye Sermaye Piyasası - Merkezi  
Saklanması ve Veri Depolama Kuruluşu

## New Business Relation

Related Companies

Related Funds

New Business Relation	
Update Notification Flag	Hayır (No)
Correction Notification Flag	Hayır (No)
Date Of The Previous Notification About The Same Subject	-
Postponed Notification Flag	Hayır (No)
Announcement Content	
Nature Of The Other Party With Which New Business Relation Will Start	Tedarikçi (Supplier)
Name Surname Or Company Title Of Customer Or Supplier	Pfizer PFE İlaçları Anonim Şirketi
If Exists Share Of Customer Or Supplier In Net Sales Or Cost Of Goods Sold On Latest Disclosed Profit Or Loss And Other Comprehensive Income Statement Of Company	0
If Exists Share Of Customer Or Supplier In Trade Receivables Or Debts On Latest Disclosed Statement of Financial Position Of Company	0
Expected Starting Date Of New Business Relation	01/05/2026
If Exist Significant Provisions Of The Contract	Summarized below.
Impact Of New Business Relation On Company Activities	Positive impact is expected.
Explanations	

-Unofficial Translation-

A Promotion, Sales, Distribution and Marketing Authorization Transfer Agreement has been signed between the two companies, effective for a period of 5 (five) years starting on May 1, 2026, for the purpose of Gen İlaç ve Sağlık Ürünleri Sanayi ve Ticaret A.Ş. (GEN) exclusively conducting business operations and transactions in Türkiye, related to the sales, marketing, promotion and distribution of the products listed below, for which Pfizer PFE İlaçları Anonim Şirketi is the marketing authorization holder.

ELELYSO® 200 U Lyophilized Powder for IV Infusion Solution: It is used in the treatment of Gaucher Disease, a rare, genetic, and hereditary metabolic disorder characterized by the accumulation of certain fatty substances (lipids) in organs such as the spleen, liver, and bone marrow due to their inability to be broken down.

BESPONSA 1 mg Powder for Concentrate for the Preparation of Infusion Solution: It is used in the treatment of patients diagnosed with Precursor B-cell Acute Lymphoblastic Leukemia (ALL)—an aggressive type of blood cancer caused by the uncontrolled and rapid proliferation of lymphoblasts (the precursors of white blood cells known as lymphocytes) in the bone marrow—who are Philadelphia chromosome-negative and demonstrate CD22 positivity as confirmed by histopathological or flow cytometric analysis.

In case of any discrepancy between the Turkish and English texts, the Turkish text shall prevail.

We proclaim that our above disclosure is in conformity with the principles set down in “Material Events Communiqué” of Capital Markets Board, and it fully reflects all information coming to our knowledge on the subject matter thereof, and it is in conformity with our books, records and documents, and all reasonable efforts have been shown by our Company in order to obtain all information fully and accurately about the subject matter thereof, and we’re personally liable for the disclosures.